Projects in development
The following projects are currently in development. If you would like to be involved in the planning stages or join the mailing list for a specific project, please email the project lead to express your interest.
TXA for HMB in acute VTE
Tranexamic acid is an effective antifibrinolytic drug that can reduce heavy menstrual bleeding. Despite excellent safety data showing negligible increased risk of thrombosis across millions of patient years, its use in women with heavy menstrual bleeding who have a recent venous thromboembolic event remains controversial. The goal of this project is to 1) survey clinicians to understand current practice, 2) gather observational data, and 3) work towards a pilot Randomised Control Trial.
HaemSTAR project lead: Eman Hassan | Email
MATRON
Our Maternal Audit on ThRombolysis Outcome and DecisioN will look at the use of thrombolysis for pregnant women with venous thromboembolism. The aims of the project are to 1) survey clinicians to understand their current practice, and 2) gather observational data.
HaemSTAR project lead: Giulia Simini | Email
Apixaban thrombo-prophylaxis in multiple myeloma
It is recommended that multiple myeloma patients treated with IMIDs such as thalidomide and lenalidomide be offered prophylactic anticoagulation due to the high risk of VTE. We understand that practice in the UK has shifted considerably and despite a lack of evidence, clinicians now favour the use of oral factor anti-Xa inhibitors, often apixaban, for this purpose. The aim of this project is to perform a retrospective, observational study to document thrombosis and bleeding outcomes in patients who receive this treatment compared to those who receive low molecular weight heparin.
HaemSTAR project lead: Phil Weir | Email
Patient-led research in sickle cell disease
We have formed a working group to develop project ideas in sickle cell disease based on patient-involvement. We hope that this will lead to high quality research that can impact patient management in a meaningful way.
HaemSTAR project lead: Christina Crossette-Thambiah | Email
Venesection for idiopathic and secondary erythrocytosis
The evidence for meaningful benefit of venesection in patients with idiopathic and secondary erythrocytosis is extremely scanty. We understand that practice is highly heterogeneous with some clinicians advocating venesection to maintain haematocrit <0.55 for example, and others not venesecting at all. We aim to 1) understand the variations in practice and the reasons for this, 2) gather retrospective, observational data on the outcomes of patients who are venesected vs not venesected, and 3) work towards a randomised controlled trial.
HaemSTAR project lead: Pip Nicolson | Email
Audit of management of neonatal ITP
Neonatal ITP is a rare disease and clinical practice is likely heterogeneous. The aim of this project is to prospectively audit care in such cases focusing on protocols, neonatal management and maternal counselling.
HaemSTAR project lead: Olga Tsiamita | Email